FDA Commissioner Scott Gottlieb to Step Down

A successor has not yet been named and it is expected that Gottlieb will leave the position sometime next month.

Scott Gottlieb

FDA Commissioner Scott Gottlieb is stepping down nearly two years after he was appointed to the top position at the regulatory agency. The news comes after Gottlieb went on Twitter in January to deny reports that he would be leaving the position. 

A successor has not yet been named and it is expected that Gottlieb will leave the position sometime next month. President Trump took to social media Tuesday afternoon to thank Gottlieb for his service.

Gottlieb has carved out a tremendous reputation for himself during his short tenure as FDA Commissioner. He has taken a tough stance on tobacco, underaged vaping, and has taken an aggressive stance on the opioid epidemic. Gottlieb helped guide FDA through a grueling government shut down.  He was well respected in the medtech industry and most recently was working on transformative new steps to modernize the agency's 510(k) program to keep pace with the increasing complexity of rapidly evolving medical technology.

Scott Whitaker, president and CEO of Advanced Medical Technology Association (AdvaMed) gave the outgoing commissioner high praise Tuesday afternoon.

“We want to thank Dr. Gottlieb for his service to the American public and his commitment to ensuring patients have access to the latest treatments, diagnostics and cures,” Whitaker said in a release. “During his tenure as FDA commissioner, Dr. Gottlieb has been a tireless advocate for improved patient care and for promoting innovative solutions to our most pressing health challenges, including greater use of medtech to combat the opioid crises. We wish him well in his future endeavors.”

Health and Human Services Secretary Alex Azar commended Gottlieb and in a statement said that the outgoing FDA Commissioner’s, “leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use, chronic disease, and more.”

Gottlieb has served several roles in the agency including deputy commissioner for the medical and scientific affairs and as a senior advisor to FDA commissioner.

 

500 characters remaining